[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:complex-karyotype":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Complex Karyotype",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z"]